Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment

[Image: see text] Delamanid (DLM) is a hydrophobic small molecule therapeutic used to treat drug-resistant tuberculosis (DR-TB). Due to its hydrophobicity and resulting poor aqueous solubility, formulation strategies such as amorphous solid dispersions (ASDs) have been investigated to enhance its aq...

Descripción completa

Detalles Bibliográficos
Autores principales: Caggiano, Nicholas J., Armstrong, Madeleine S., Georgiou, Joanna S., Rawal, Aditya, Wilson, Brian K., White, Claire E., Priestley, Rodney D., Prud’homme, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481377/
https://www.ncbi.nlm.nih.gov/pubmed/37578286
http://dx.doi.org/10.1021/acs.molpharmaceut.3c00240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481377/
https://www.ncbi.nlm.nih.gov/pubmed/37578286
http://dx.doi.org/10.1021/acs.molpharmaceut.3c00240

Ejemplares similares